Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | EML4 - ALK ALK K1150dup |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| EML4 - ALK ALK K1150dup | lung adenocarcinoma | predicted - resistant | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, ALK K1150dup was identified at the time of progression on Lorbrena (lorlatinib) in a patient with lung adenocarcinoma harboring EML4-ALK (PMID: 42129432). | 42129432 | |
| EML4 - ALK ALK K1150dup | Advanced Solid Tumor | resistant | Lorlatinib | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing ALK K1150dup in the context of EML4-ALK were resistant to Lorbrena (lorlatinib) treatment in culture (PMID: 42129432). | 42129432 | |
| EML4 - ALK ALK K1150dup | Advanced Solid Tumor | resistant | NVL-655 | Preclinical - Cell culture | Actionable | In a preclinical study, cells expressing ALK K1150dup in the context of EML4-ALK were resistant to NVL-655 treatment in culture (PMID: 42129432). | 42129432 |